| Tumor-targeted Salmonella as a Novel Anticancer Vector JM Pawelek, KB Low, D Bermudes Cancer research 57 (20), 4537-4544, 1997 | 755 | 1997 |
| Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo KB Low, M Ittensohn, T Le, J Platt, S Sodi, M Amoss, O Ash, E Carmichael, ... Nature biotechnology 17 (1), 37-41, 1999 | 569 | 1999 |
| Tumour-targeting bacteria engineered to fight cancer S Zhou, C Gravekamp, D Bermudes, K Liu Nature Reviews Cancer 18 (12), 727-743, 2018 | 536 | 2018 |
| Bacteria as tumour-targeting vectors JM Pawelek, KB Low, D Bermudes The lancet oncology 4 (9), 548-556, 2003 | 412 | 2003 |
| Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain of Salmonella typhimuvium C Clairmont, KC Lee, J Pike, M Ittensohn, KB Low, J Pawelek, ... Journal of Infectious Diseases 181 (6), 1996-2002, 2000 | 394 | 2000 |
| In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy P Tardi, S Johnstone, N Harasym, S Xie, T Harasym, N Zisman, P Harvie, ... Leukemia research 33 (1), 129-139, 2009 | 387 | 2009 |
| Kinetics and pattern of organelle exocytosis duringToxoplasma gondii/host-cell interaction JF Dubremetz, A Achbarou, D Bermudes, KA Joiner Parasitology research 79, 402-408, 1993 | 259 | 1993 |
| Symbiosis as a mechanism of evolution: status of cell symbiosis theory L Margulis, D BERMUDES Symbiosis, 1985 | 258 | 1985 |
| Use of preferentially replicating bacteria for the treatment of cancer M Sznol, SL Lin, D Bermudes, L Zheng, I King The Journal of clinical investigation 105 (8), 1027-1030, 2000 | 253 | 2000 |
| Tandemly repeated genes encode nucleoside triphosphate hydrolase isoforms secreted into the parasitophorous vacuole of Toxoplasma gondii. D Bermudes, KR Peck, MA Afifi, CJ Beckers, KA Joiner Journal of Biological Chemistry 269 (46), 29252-29260, 1994 | 184 | 1994 |
| Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts WS Lim, PG Tardi, N Dos Santos, X Xie, M Fan, BD Liboiron, X Huang, ... Leukemia research 34 (9), 1214-1223, 2010 | 164 | 2010 |
| Melanoma× macrophage hybrids with enhanced metastatic potential M Rachkovsky, S Sodi, A Chakraborty, Y Avissar, J Bolognia, ... Clinical & experimental metastasis 16, 299-312, 1998 | 156 | 1998 |
| Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates SM Ansell, SA Johnstone, PG Tardi, L Lo, S Xie, Y Shu, TO Harasym, ... Journal of medicinal chemistry 51 (11), 3288-3296, 2008 | 154 | 2008 |
| Antitumor effect of VPN20009, an attenuated Salmonella, in murine tumor models. X Luo, Z Li, L Zheng, S Lin, T Le, M Ittensohn, D Bermudes, JD Runyab, ... | 153 | 2001 |
| Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent I King, D Bermudes, S Lin, M Belcourt, J Pike, K Troy, T Le, M Ittensohn, ... Human gene therapy 13 (10), 1225-1233, 2002 | 150 | 2002 |
| Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo PG Tardi, N Dos Santos, TO Harasym, SA Johnstone, N Zisman, ... Molecular cancer therapeutics 8 (8), 2266-2275, 2009 | 149 | 2009 |
| Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans KB Low, M Ittensohn, X Luo, LM Zheng, I King, JM Pawelek, D Bermudes Suicide Gene Therapy: Methods and Reviews, 47-59, 2004 | 139 | 2004 |
| Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK SA Soghomonyan, M Doubrovin, J Pike, X Luo, M Ittensohn, JD Runyan, ... Cancer gene therapy 12 (1), 101-108, 2005 | 133 | 2005 |
| Genetically modified tumor-targeted bacteria with reduced virulence D Bermudes, KB Low, Vion Pharmaceuticals, Inc., Y University US Patent 6,080,849, 2000 | 124* | 2000 |
| Live bacteria as anticancer agents and tumor-selective protein delivery vectors. D Bermudes, LM Zheng, IC King Current opinion in drug discovery & development 5 (2), 194-199, 2002 | 119 | 2002 |
Sharon JohnstoneScientist, WL GoreVerified email at wlgore.com
